PT - JOURNAL ARTICLE AU - Huang, Ching-I AU - Crump, Ronald E AU - Brown, Paul E AU - Spencer, Simon E F AU - Miaka, Erick Mwamba AU - Shampa, Chansy AU - Keeling, Matt J AU - Rock, Kat S TI - Identifying regions for enhanced control of <em>gambiense</em> sleeping sickness in the Democratic Republic of Congo AID - 10.1101/2020.07.03.20145847 DP - 2021 Jan 01 TA - medRxiv PG - 2020.07.03.20145847 4099 - http://medrxiv.org/content/early/2021/04/12/2020.07.03.20145847.short 4100 - http://medrxiv.org/content/early/2021/04/12/2020.07.03.20145847.full AB - Gambiense human African trypanosomiasis (sleeping sickness, gHAT) is a disease targeted for elimination of transmission (EOT) by 2030. Despite the number of new cases reported annually being at a historical minimum, the likelihood of achieving EOT is unknown. We utilised modelling to study the impact of four strategies comprised of currently-available intervention methods including active and passive screening and vector control (VC) on transmission across 168 health zones in the Democratic Republic of the Congo. By estimating the median year of EOT and the probability of EOT by 2030 under each strategy, the model predicts only 81 health zones are on track to achieve the EOT target using medical-only strategies and this number drops to 52 when uncertainty is considered (&gt; 90% probability). Although all health zones are predicted to meet EOT by 2030 under strategies with VC, blanket coverage is impractical so this analysis provides a priority list of health zones for consideration for supplementary VC implementation in conjunction with medical interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported, in whole or in part, by the Bill &amp; Melinda Gates Foundation [OPP1177824, OPP1184344, OPP1156227, OPP1186851, OPP1155293]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. This work was also supported by the Belgian Development Agency (ENABEL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe gHAT data were obtained from the WHO HAT Atlas and are subject to a data sharing agreement. Interested parties should apply to WHO in order to gain access to these data. Results for each health zone level projection can be viewed on the paper's companion website. Code and model outputs are available from the OSF. https://hatmepp.warwick.ac.uk/projections/v1 https://osf.io/jza27/?view_only=d523cb1edf9c4828bc63cb197e5000b2